PRESS RELEASE DUBLIN.

Women's Wellness Alliance, an organization centered on promoting high-quality, affordable healthcare for women, announced an contract to create LILETTA® 52 mg open to individuals across USWHA's 26 Alliance ongoing health care groups nationwide. The agreement paves the true way for 1,500 Alliance physicians to provide LILETTA as a contraceptive option to the an incredible number of reproductive-age women that they care for in the united states. Logo -ttp://photos.prnewswire.com/p. As a head in females's healthcare, theU.S. Women's Wellness Alliancebelieves in offering safe and sound, effective treatment options to our sufferers, and the IUD is among the most efficacious types of contraception out there, saidJack Feltz, MD, President of President/CEO and USWHA ofLifeline Medical Associates, LLCinNew Jersey.ASSURE study of experimental agent to raise HDL yields ‘disappointing and surprising’ results The search continues for a realtor that increases high-density lipoprotein and reduces arterial plaque, following the experimental apolipoprotein A1 inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation study. Having less efficacy of RVX-208 is amazing and disappointing, given promising earlier results, noted business lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Medical and Health Study Institute, Professor of Cardiology at the University of Adelaide and Consultant Cardiologist at the Royal Adelaide Medical center in Adelaide, Australia.